http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201800379-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-481 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B6-00 |
| filingDate | 2018-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201800379-A1 |
| titleOfInvention | METHOD OF DIAGNOSTIC BREAST CANCER |
| abstract | The invention relates to medicine, namely to radiation diagnosis, and can be used in oncology and mammology. The invention is directed to improving the diagnosis of breast cancer. A method for diagnosing breast cancer includes a contrast spectral mammography with the inclusion of an additional delayed phase in the study protocol — a contrast spectral mammography for 9-12 minutes from the start of intravenous contrast administration. Contrast spectral mammography was performed on a Senographe Essential (GE) digital mammography unit with a contrast spectral mammography (CESM) function — a immediately recombinant image was obtained. As a contrast agent, iodine-containing contrast agent was used with an iodine concentration of 300 mg / ml, administered intravenously at a rate of 3 ml / s at a rate of 1.5 ml / kg of weight, but not more than 100 ml. Mammograms were performed in two projections after intravenous administration to the patient of an iodine-containing contrast agent: in the cranio-caudal (CC) and medio-lateral (MLO), from 2 to 5 minutes and from 9 to 12 minutes from the start of the injection of the contrast drug. The compression time for each breast was no more than 15 s. Processed recombinant images were transmitted directly to the workstation for interpretation by the radiologist of the mammography room. The total effective equivalent dose varied from 1.4 to 3.6 mGy, depending on the size and structural type of the mammary gland. The proposed method allows to improve the diagnosis of breast cancer with the definition of a more accurate size, localization and prevalence (nodal, multifocal, multicentric, edematous-infiltrative forms of growth) of the main process, the positive prognostic value of the method was 97.7%. |
| priorityDate | 2017-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID807 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554831 |
Total number of triples: 14.